First-line cisplatin, docetaxel, and cetuximab for patients with recurrent or metastatic head and neck cancer: A multicenter cohort study

Table 5 Selected studies that assessed first-line TPEx schema in patients with recurrent or metastatic head and neck cancer

Ref.	Study type	n	ORR (%)	PFS (mo)	OS (mo)	Grade 3, adverse events (%)	Grade 4, adverse events (%)
Guigay et al[19]	Phase 2	541	57.6	6.0	14.5	73	33
Guigay et al[14]	Phase 2	54	44.4	6.2	14	93	22
Bossi et al[15]	Phase 21	201	51.7	7.0	11	73	33
Even et al[21]	Retrospective	30	87	6.0	13.6	17	10
Fuchs et al[22]	Retrospective	38	50	6.3	10.8	100

¹This trial used paclitaxel.

ORR: Overall response rate; PFS: Progression-free survival; OS: Overall survival.